Drug Trial Radar · NCT07140016
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 22, 2025
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Aug 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with non small cell lung cancer (NSCLC) have a faulty ALK gene. ALK stands for anaplastic lymphoma kinase. People with NSCLC who have the faulty ALK gene are called ALK-positive. ALK inhibitors are an approved treatment for people with ALK positive NSCLC. Some people stop responding to treatment with ALK inhibitors over time due to more changes happening in their faulty ALK gene, so there is an unmet medical need. Gilteritinib is an approved treatment for people with acute myeloid leukemia (AML) with the faulty FLT3 gene who haven't responded to previous treatment, or their cancer came back after previous treatment. Gilteritinib also blocks changes in the ALK gene which could help people with ALK-positive NSCLC. A study needs to be done with gilteritinib in people with ALK-positive NSCLC. The main aim of the study is to check the safety of gilteritinib in people with ALK-positive NSCLC and if they tolerate gilteritinib. People in this study will be adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC). Locally advanced means the cancer has spread to nearby tissue. Metastatic means the cancer has spread to other parts of the body. They have stopped responding to treatment with ALK inhibitors, including alectinib or lorlatinib, over time. The key reasons people cannot take part are if they have symptomatic cancers in the brain or nervous system, their cancer has spread to the thin tissue that covers the brain and spinal cord (leptomengingeal metastasis), have recently had or planning to have major surgery, have certain heart conditions, or have recently had an infection, a stroke or mini-stroke. People in the study will take tablets of gilteritinib once a day in a 28-day cycle. They may be given up to 2 different doses of gilteritinib. People in the study will start on the lower dose but can eventually switch to the higher dose if they tolerate the lower dose and meet the safety checks. Whilst taking gilteritinib, people will have regular scans of their tumors. People will continue taking gilteritinib until their cancer gets worse, they have medical problems from gilteritinib that they can't tolerate, they ask to stop taking gilteritinib, they start other cancer treatment or, sadly pass away. People will visit the clinic about 7 days and then 30 days after they stop taking gilteritinib. They will be asked about any medical problems and will have a safety check. After this, people who stopped taking gilteritinib, but their cancer hadn't become worse, will continue to have regular scans of their tumors. If their cancer does get worse, they will no longer have scans of their tumors. After finishing gilteritinib, people will be phoned every 12 weeks to check on their health. People will be in the study for up to 4 years, depending on how they respond to gilteritinib.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Anaplastic Lymphoma Kinase (ALK) Positive
Interventions
gilteritinibDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting Toxicity (DLT)Time frame: Up to 28 Days
- Number of participants with Adverse Events (AEs)Time frame: Up to approximately 53 Months
- Number of participants with Serious Adverse Events (SAEs)Time frame: Up to approximately 53 Months
- Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to approximately 53 Months
- Number of participants with vital sign abnormalities and/or adverse events (AEs)Time frame: Up to approximately 53 Months
- Number of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)Time frame: Up to approximately 53 Months
- Number of participants with physical exam abnormalities and/or adverse events (AEs)Time frame: Up to approximately 53 Months
- Number of participants at each grade of Eastern Cooperative Oncology Group (ECOG) performance status scoreTime frame: Up to approximately 53 Months
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
Providence Medical Foundation - Fullerton - Virginia K. Crosson Cancer Center
Fullerton, California · Recruiting
University of California - Irvine
Orange, California · Recruiting
Vail Health Hospital - Shaw Cancer Center
Edwards, Colorado · Recruiting
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
OSF Health Care
Peoria, Illinois · Recruiting
University of Michigan Health Systems
Ann Arbor, Michigan · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Hackensack University Medical Center
Hackensack, New Jersey · Withdrawn
UT Southwestern Medical Center at Dallas
Dallas, Texas · Recruiting
Virginia Cancer Specialists PC
Fairfax, Virginia · Recruiting
Site FR33008
Saint-Herblain, France · Recruiting
Site FR33005
Toulouse, France · Recruiting
Site FR33001
Villejuif, France · Recruiting
Site ES34017
Barcelona, Spain · Recruiting
Site ES34006
Madrid, Spain · Recruiting
Site ES34011
Madrid, Spain · Recruiting
Site ES34008
Málaga, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.